Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: New Constructs, LLC
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sangamo Biosciences Inc Reaffirms FY 2013 Revenue Guidance

Wednesday, 24 Jul 2013 04:02pm EDT 

Sangamo Biosciences Inc announced that for fiscal 2013, it expects revenues to be in the range of $20 to $24 million. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $21 million for fiscal 2013. 

Company Quote

-0.65 -5.19%
4:00pm EDT